Galashiels-based pharmaceutical company ProStrakan has announced a deal with a US firm which could be worth up to �80m over the next 15 years.
The deal with biotech giant Amgen is worth about �4.5m initially.
Under the agreement, the company gets exclusive rights to develop and commercialise ProStrakan's pre-clinical compounds for kidney disease.
The news comes after the Borders company recently revealed sales of �16m for the first six months of the year.
ProStrakan CEO Dr Wilson Totten said he was delighted to have entered into the US deal.
One-Minute World News
News services
E-mail this to a friend
Printable version
